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Deguelin, A PI3K/AKT inhibitor, enhances chemosensitivity of
leukaemia cells with an active PI3K/AKT pathway
Phosphoinositide 3 kinase (PI3K), a lipid kinase, generates
3¢-phosphoinositides that recruit proteins containing lipid-
recognition domains (pleckstrin homology domains, FYVE
domains) to the plasma membrane. PI3K signalling regulates
cell growth, motility and survival (Lu et al, 2003; Fresno Vara
et al, 2004). The 3¢-phosphoinositides attract phosphoinosi-
tide-dependent kinase 1 (PDK1) to the plasma membrane and
Akt. PDK1 activates Akt by phosphorylation of Thr 308
residue in the activation loop, although full activation requires
phosphorylation of Ser 473 in the C-terminal hydrophobic
motif of Akt. The latter phosphorylation step is effected by a
kinase that has not been conclusively identified to date (Brazil
et al, 2004; Hanada et al, 2004). The serine/threonine kinase
Akt is the major mediator of survival signals that protect cells
from apoptosis because of its ability to phosphorylate and
inactivate several downstream targets such as pro-apoptotic
protein BAD, caspase-9, ASK1, and transcription factors of the
FoxO family (Brazil & Hemmings, 2001; Mitsiades et al, 2004).
Because Akt and its upstream regulators are deregulated in a
wide range of solid tumours and haematological malignancies
(Kim et al, 2005), the PI3K/Akt signalling network is con-
sidered as a key determinant of the biological aggressiveness of
these tumours, as well as a major potential target for novel
anti-cancer therapies (Mitsiades et al, 2004). Pharmacological
inhibitors that target PI3K (LY294002, wortmannin) have been
widely used for in vitro studies on cancer cell lines, in which
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Activation of the phosphoinositide 3 kinase (PI3K)/Akt signalling pathway
has been linked with resistance to chemotherapeutic drugs, and its
downregulation, by means of PI3K inhibitors, lowers resistance to various
types of therapy in tumour cell lines. Recently, it has been reported that
deguelin, a naturally occurring rotenoid, is a powerful inhibitor of PI3K. We
investigated whether or not deguelin could enhance the sensitivity to
chemotherapeutic drugs of human U937 leukaemia cells and acute myeloid
leukaemia (AML) blasts with an activated PI3K/Akt network. Deguelin
(10 nmol/l) induced S phase arrest with interference of progression to G2/M,
and at 100 nmol/l significantly increased apoptotic cell death of U937. At
10–100 nmol/l concentrations, deguelin downregulated Akt phosphorylation
of leukaemia cells and markedly increased sensitivity of U937 cells to
etoposide or cytarabine. A 10 nmol/l concentration of deguelin did not
negatively affect the survival rate of human cord blood CD34+ cells, whereas
it increased sensitivity of AML blasts to cytarabine. Deguelin was less toxic
than wortmannin on erythropoietin- and stem cell factor-induced
erythropoiesis from CD34+ progenitor cells. Overall, our results indicate
that deguelin might be used in the future for increasing sensitivity to
therapeutic treatments of leukaemia cells with an active PI3K/Akt signalling
network.
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they induce apoptosis or increase sensitivity to chemothera-
peutic drugs (or both) (West et al, 2002). However, neither
wortmannin nor LY294002 is entirely specific for the PI3K/Akt
pathway, as wortmannin also inhibits phospholipases C, D and
A2, while LY294002 downregulates casein kinase 2 activity
(West et al, 2002). Furthermore, the effect of LY294002 on
PI3K is rapidly reversible, and problems with the toxicity and
pharmacokinetics of these drugs have been encountered (West
et al, 2002). For these reasons, it seems unlikely that LY294002
or wortmannin may be fully developed as cancer therapeutics
(Gills & Dennis, 2004).
Very recently, it has been shown that the naturally occurring
rotenoid, deguelin, inhibited PI3K activity and reduced Akt
phosphorylation in premalignant and malignant bronchial
epithelial cells (Chun et al, 2003). In vitro deguelin treatment,
at doses attainable in vivo (Udeani et al, 2001), inhibited the
growth and induced apoptosis of premalignant and malignant
bronchial cells but had minimal effect on normal bronchial
cells.
Considering that activation of the PI3K/Akt pathway is
being increasingly recognized as a factor undermining the
successful therapeutic treatment of human leukaemias (Neri
et al, 2003; Xu et al, 2003; Tazzari et al, 2004; Zhao et al,
2004), we decided to investigate whether or not deguelin could
be employed to enhance the sensitivity of human leukaemia
cells with an active PI3K/Akt pathway to chemotherapeutic
drugs employed for the treatment of acute myeloid leukaemia
(AML). Indeed, it is well established that activation of the
PI3K/Akt pathway contributes to the resistance of human
leukaemia cells to chemotherapeutic agents (Martelli et al,
2003; Xu et al, 2003; Tabellini et al, 2004).
Here, we showed that deguelin, when employed for 24 h at
10 nmol/l concentration, arrested proliferation of U937 cells
without inducing apoptosis. At this concentration, deguelin
dephosphorylated Akt and increased U937 cell sensitivity to
etoposide and cytarabine. Remarkably, at 10 nmol/l deguelin
enhanced the sensitivity to cytarabine of AML blasts with an
active PI3K/Akt pathway.
These data suggest that deguelin might be employed in the
future for enhancing the sensitivity of leukaemia cells to
conventional forms of therapy.
Experimental procedures
Chemicals and antibodies
Etoposide, cytarabine, bovine serum albumin (BSA, Fraction
V), fetal calf serum (FCS), Roswell Park Memorial Institute
(RPMI) 1640 medium, monoclonal antibody to b-tubulin and
peroxidase-conjugated secondary antibodies were from Sigma,
St Louis, MO, USA. The Complete Protease Inhibitor Cocktail,
and the Lumi-LightPlus enhanced chemiluminescence (ECL)
detection kit were from Roche Applied Science, Milan, Italy.
Wortmannin was from Calbiochem, La Jolla, CA, USA.
Deguelin was purchased from Alexis Biochemical, Laufelfin-
gen, Switzerland. The Protein Assay kit (detergent compatible)
was from Bio-Rad, Hercules, CA, USA. Rabbit polyclonal
antibodies to total Akt, Thr 308 phosphorylated Akt (p-Akt),
Ser 473 p-Akt, total p44/42 mitogen-activated protein (MAP)
kinase, Thr 202/Tyr 204 p-p44/42 MAP kinase, total p38 MAP
kinase, and Thr 180/Tyr 182 p-p38 MAP kinase were from Cell
Signalling Technology, Beverly, MA, USA. Phycoerythrin
(PE)–conjugated anti-glycophorin A (GPA) monoclonal anti-
body and fluorescein isothiocyanate (FITC)–conjugated anti-
CD71 monoclonal antibody were from DAKO AS, Glostrup,
Denmark.
Cell culture
U937 and HL60PT (for parental, obtained from the American
Type Culture Collection-CCL 240) cells were routinely main-
tained in RPMI 1640 medium supplemented with 10% FCS at
an optimal cell density of 3–8 · 105 cells/ml.
Isolation of human umbilical cord blood CD34+ cells
Cord blood (CB) samples were collected according to the
institutional guidelines after informed consent. The CB
mononuclear cells, isolated by density gradient centrifugation
(Ficoll/Histopaque, 1077 g/ml), were left to adhere to plastic
for at least 2 h at 37C. After removal of adherent cells, CD34+
cells were isolated using a magnetic cell-sorting program
(Mini-MACS) and the CD34 isolation kit (Miltenyi Biotec,
Bergish Gladbach, Germany) following the manufacturer’s
instructions. The purity of CD34+ selected cells ranged
between 93% and 98%, and was determined by flow cytometry
using a PE-conjugated monoclonal antibody that recognizes a
separate epitope of the CD34 molecule (581, Beckman Coulter,
Miami, FL, USA). Cord blood CD34+ cells were cultured in
Ex-vivo-20 (BioWhittaker, Walkersville, MD, USA) serum-free
medium supplemented with nucleosides (10 lg/ml each),
0Æ5% BSA, 10 lg/ml insulin, 200 lg/ml iron-saturated trans-
ferrin, 50 lmol/l 2-mercaptoethanol, 5 ng/ml interleukin (IL)
)3, 50 ng/ml stem cell factor (SCF), and 10 ng/ml IL-6
(complete medium). For erythroid differentiation, cells were
incubated for 6 d in complete medium containing 5 U/ml
erythropoietin (EPO) and 50 ng/ml SCF without IL-3 and
IL-6. Samples were then double stained with anti-CD71-FITC
and anti-glycophorin A and analysed by flow cytometry.
Isolation and culture of AML blasts
Samples from AML patients were obtained at diagnosis from
peripheral blood, following informed consent according to the
ethical standards of the institutional guidelines. The AML cases
were defined according to the classification of the French-
American-British (FAB) committee. All samples had >80%
blasts after Ficoll-Hypaque density-gradient centrifugation, as
assessed by flow cytometric analysis with anti-CD13, CD33,
CD34 antibodies (alone or in combination). AML blasts
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(1 · 106/ml) were cultured in methylcellulose medium
(Methocult, Stem Cell Technologies, Vancouver, Canada)
supplemented with human recombinant growth factors: IL-3
(20 ng/ml), IL-6 (20 ng/ml), SCF (50 ng/ml).
Induction and detection of apoptosis
Cell lines were treated with etoposide (5 lg/ml) or cytarabine
(0Æ3 lmol/g) for 6 h at 37C. In some experiments, prior to
apoptosis induction, cells had been pre-incubated for 24 h
with wortmannin (100 nmol/l) or deguelin at the indicated
concentrations. For experiments on CD34+ cells and AML
blasts, cytarabine was employed at 0Æ1 lmol/l (Frelin et al,
2005). For detection of apoptosis, samples containing 2 · 105
cells were harvested by centrifugation at 200 g for 10 min,
fixed with 70% cold ethanol for 1 h, and subsequently stained
with propidium iodide (PI, DNA-Prep kit, Beckman Coulter).
The subdiploid DNA content was calculated using an Epics XL
flow cytometer with the appropriate software (Beckman
Coulter). At least 10 000 events/sample were acquired. In
some cases, cells were also stained with Annexin V-FITC
(Roche Applied Science) as reported elsewhere (Zhao et al,
2004). Briefly, cells were washed in phosphate-buffered saline
(PBS, pH 7Æ4) and resuspended in 100 ll of binding buffer
containing Annexin V-FITC. Cells were analysed by flow
cytometry after addition of PI. Annexin V-FITC binds to those
cells that express phosphatidylserine on the outer layer of the
cell membrane, and PI stains the cellular DNA of those cells
with a compromised cell membrane. This enabled live cells
(unstained with either fluorochrome) to be discriminated from
apoptotic cells (stained only with Annexin V-FITC) and
necrotic cells (stained with both Annexin V and PI) (Vermes
et al, 1995). Results obtained with Annexin V-FITC technique
were always nearly superimposable to those given by the
subdiploid DNA content analysis, as far as the percentage of
apoptotic cells was concerned.
Protein concentration assay
This was performed according to the manufacturers’ instruc-
tions using the detergent compatible Bio-Rad Protein Assay.
Preparation of cell homogenates and Western blot analysis
Cells were washed twice in PBS, then lysed (107/ml) in
10 mmol/l Tris–HCl, pH 7Æ4, 1 mmol/l MgCl2, 1 mmol/l
EGTA, 1% Triton X-100, 0Æ25 mol/l sucrose, containing the
Complete Protease Inhibitor Cocktail supplemented with
50 mmol/l NaF, 1 mmol/l 2-glycerophosphate, 25 mmol/l
NaPPi. After 15 min on ice, the cells were homogenized by
10 passages through a 25 gauge needle, and centrifuged in a
microfuge (9300 g) for 10 min at 4C. An aliquot of the
supernatant was saved for protein assay. Supernatants were
mixed with 4 · electrophoresis sample buffer, then protein
(80 lg/lane), was separated by sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE), and trans-
ferred to nitrocellulose sheets using a semi-dry blotting
apparatus. Sheets were saturated in PBS containing 5% normal
goat serum, 4% BSA, 0Æ25 non-fat dried milk (blocking buffer)
for 60 min at 37C, then incubated overnight at 4C in
blocking buffer containing the primary antibody. After four
washes in PBS containing 0Æ1% Tween-20, the sheets were
incubated for 30 min at room temperature with the appro-
priate peroxidase-conjugated secondary antibody, diluted
1:5000 in blocking buffer, and washed as above. Bands were
visualized by the ECL method.
Statistical evaluation
The data are given as mean values ± standard error of the
mean (SEM). For statistical analyses, the Student’s t-test for
unpaired samples at the level of significance of 0Æ01 was used.
Results
Effects of deguelin on the cell cycle of human leukaemia cell
lines
As experimental systems, we chose U937 cells, which were
reported to have elevated levels of p-Akt (Matsuoka et al,
2003), and HL60PT cells, which do not have an active PI3K/
Akt pathway (Martelli et al, 2003; Neri et al, 2003). We
assessed whether deguelin affected cell growth by determining
the effects of drug on the cell cycle by flow cytometry of PI-
stained samples. When employed for 24 h at 1 nmol/l,
deguelin did not alter the cell cycle of U937 cells. However,
at 10 nmol/l, deguelin significantly increased the percentage of
G2/M cells and decreased that of S phase cells (Table I). A
100 nmol/l concentration of deguelin induced a significant
increase of apoptotic cells in U937 cells, as demonstrated by
Annexin V-FITC staining. In contrast, deguelin (either 10 or
100 nmol/l) did not affect the cell cycle and apoptosis of HL60
PT cells (Table I).
Deguelin downregulates Akt phosphorylation in leukaemia
cell lines with an active PI3K/Akt axis
Deguelin is a recently recognized PI3K inhibitor. Therefore, we
decided to investigate the effects of deguelin on the phos-
phorylation levels of Akt, a downstream target of PI3K. As
given in Fig 1, Western blot analysis with phospho-specific
antibodies confirmed the presence, in these two cell lines, of
high levels of both Thr 308 p-Akt and Ser 473 p-Akt. Akt
phosphorylation was downregulated by wortmannin. A 24-h
incubation with 1 nmol/l deguelin did not decrease the Akt
phosphorylation, and consistently showed lack of effect on the
cell cycle. However, if the concentration was raised to 10 or
100 nmol/l, the effects of deguelin on the p-Akt levels were
very evident. At 10 or 100 nmol/l, deguelin was more effective
than wortmannin (100 nmol/l) in inhibiting Akt phosphory-
Deguelin inhibits PI3K/Akt in leukaemia cells
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lation. Total Akt expression was unchanged by deguelin.
Moreover, deguelin did not affect the expression or the
phosphorylation levels of either p44/42 or p38 MAP kinases in
U937 cells. Total Akt expression was not affected by deguelin
also in HL60PT cells. These cells displayed almost undetectable
levels of p-Akt, in agreement with our own previous results
(Martelli et al, 2003; Neri et al, 2003).
Deguelin increases sensitivity of human leukaemia cells to
chemotherapeutic drugs
As the PI3K/Akt signalling pathway plays a fundamental role in
cell survival, we wanted to verify whether deguelin, at
concentrations which promote Akt dephosphorylation, could
enhance sensitivity of U937 cells to chemotherapeutic drugs,
i.e. a treatment known to induce cell death through apoptosis.
As presented in Fig 2A, 1 nmol/l deguelin did not increase
the rate of apoptotic U937 cells. When employed at 10 nmol/l
it only slightly enhanced the number of apoptotic U937 cells.
In contrast, if the concentration was raised to 100 nmol/l,
deguelin alone significantly increased the percentage of apop-
totic U937 cells. However, deguelin (10 or 100 nmol/l), when
used in combination with either etoposide or cytarabine,
dramatically increased the number of U937 cells that under-
went apoptosis. In this respect, deguelin, at either concentra-
tion employed, was more effective than wortmannin. At
1 nmol/l, deguelin was not effective in sensitizing the cells to
drugs (Fig 2A).
The concept of targeting the PI3K/Akt pathway would have
more validity if the observed increases in apoptosis were
greater in cells with an over-activated pathway than in cells
with low levels of Akt phosphorylation. To address this issue,
we employed HL60PT cells, which have low levels of p-Akt and
are very sensitive to etoposide and cytarabine (Neri et al,
2003). As given in Fig 2B, deguelin (10–100 nmol/l) did not
increase the percentage of apoptotic HL60PT cells in response
to chemotherapeutic drugs.
Effect of deguelin on survival, Akt phosphorylation, and on
EPO- and SCF-induced erythropoiesis from CD34+
progenitor cells
We next sought to assess the influence of deguelin on the
survival of human umbilical CB CD34+ cells cultured in the
presence of a cocktail of cytokines. As demonstrated in Fig 3A,
wortmannin (100 nmol/l) did not increase in a significant
manner the percentage of apoptotic cells after 1 or 2 d of
culture. Deguelin gave a similar result when employed at
10 nmol/l. However, if it was used at 100 nmol/l, the
percentage of apoptotic cells significantly rose, even after 1 d
of culture.
We then investigated the effect of deguelin on the
phosphorylation state of Akt expressed by CD34+ cells. As
shown in Fig 3B, Akt was not phosphorylated on Thr 308 or
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Fig 1. Deguelin inhibits Akt phosphorylation in U937 cells. Western
blot analysis for expression of total Akt, Thr 308 p-Akt, Ser 473 p-Akt,
total p44/42 MAP kinase, Thr 202/Tyr 204 p-MAP kinase, total p38
MAP kinase and Thr 180/Tyr 182 p-p38 MAP kinase. Cells were
incubated with the pharmacological inhibitors for 24 h prior to lysate
preparations. Wortmannin was present at 100 nmol/l. Protein
(80 lg/lane) was separated by SDS-PAGE and blotted to nitrocellulose
sheets. Immunoreactive bands were visualized by the ECL technique.
Immunostaining with a monoclonal antibody to b-tubulin confirmed
equal loading. Blots are representative of three separate experiments.
Table I. Flow cytometric analysis of cell cycle in response to deguelin.
Cells were incubated with the indicated concentrations of deguelin for
24 h, then analysed for DNA content and for the percentage of cells in
specific phases of the cell cycle by means of PI staining, whereas for
detection of apoptotic cells the Annexin-FITC staining was employed.
For this reason, the sum of apoptotic cells plus cells in various phases
of the cell cycle exceeds 100%. Results are the mean value of three
different experiments ± standard deviation.
Control 1 nmol/l 10 nmol/l 100 nmol/l
U937
Apoptotic 5Æ3 ± 2Æ1 5Æ1 ± 2Æ3 8Æ4 ± 3Æ1 25Æ6 ± 4Æ8*
G1 54Æ3 ± 6Æ2 53Æ7 ± 6Æ9 48Æ7 ± 6Æ9 59Æ5 ± 7Æ3
S 21Æ4 ± 3Æ5 19Æ9 ± 2Æ7 12Æ6 ± 2Æ0* 9Æ3 ± 1Æ2*
G2/M 20Æ8 ± 3Æ3 22Æ2 ± 3Æ6 32Æ9 ± 4Æ3* 11Æ1 ± 1Æ3*
HL60PT
Apoptotic 6Æ1 ± 2Æ5 6Æ6 ± 2Æ9 7Æ9 ± 3Æ2 6Æ7 ± 2Æ3
G1 53Æ9 ± 5Æ8 52Æ9 ± 5Æ6 52Æ7 ± 6Æ8 51Æ6 ± 5Æ7
S 24Æ7 ± 3Æ9 22Æ6 ± 3Æ0 21Æ0 ± 3Æ6 22Æ9 ± 4Æ3
G2/M 17Æ2 ± 3Æ0 19Æ6 ± 2Æ5 21Æ3 ± 2Æ9 20Æ9 ± 2Æ4
*Significant differences (P < 0Æ01) in comparison with untreated
(control) cells.
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there was a dramatic increase in Akt phosphorylation, most
probably because of the stimulation exerted by SCF on PI3K
(Sui et al, 2000). Deguelin markedly inhibited Akt phosphory-
lation when employed at 10 nmol/l. At 100 nmol/l deguelin,
Akt was completely dephosphorylated.
As previous findings indicated that the PI3K inhibitor
LY294002 counteracted the EPO-dependent erythroid differ-
entiation of CD34+ progenitor cells (Myklebust et al, 2002), we
investigated whether or not deguelin negatively affected the
formation of GPA+ erythroid cells from CB CD34+ haemato-
poietic progenitor cells. The CD34+ cells were cultured for 6 d
in serum-free medium supplemented with EPO and SCF. Over
the time course of the incubation, the percentage of CD34+
cells decreased from 95Æ5% to 18Æ6%, in agreement with
previous reports (e.g. Edvardsson et al, 2004). In control
samples, approximately 41% of GPA+ cells were detected
(Fig 3C). EPO- and SCF-induced formation of GPA+ eryth-
roid cells was severely impaired by wortmannin (8%).
Deguelin (10 nmol/l) was less effective than wortmannin in
maintaining an immature phenotype, as there were 21% GPA+
cells after 6 d of culture.
Deguelin dephosphorylates Akt and increases cytarabine
sensitivity of AML blasts but not of CB CD34+
To test the effect of deguelin in primary AML blasts expressing
high levels of p-Akt, we incubated cells for 24 h in serum-free
medium supplemented with a cocktail of cytokines, because
previous results have indicated that incubation of AML blasts in
serum-free medium with no cytokines led to a decrease of Akt
phosphorylation (Zhao et al, 2004). The presence of deguelin
(10 nmol/l) during the 24-h incubation produced a dramatic
decrease in the levels of p-Akt in all of the four investigated
patients (Fig 4), whereas total Akt levels were unaffected. We
then investigated whether deguelin might increase AML blast
































Fig 2. Deguelin increases the sensitivity of
leukaemia cells to chemotherapeutic drugs. (A)
U937 cells. Cells were treated with etoposide
(5 lg/ml) or cytarabine (0Æ3 lmol/l) for 6 h. (B)
HL60PT cells. In (A) and (B) the pharmacolo-
gical inhibitors had been present for 24 h prior
to treatment with the apoptosis inducers.
Wortmannin concentration was 100 nmol/l.
Apoptotic cells were evaluated by flow cyto-
metric analysis as a subdiploid peak in PI-
stained samples. Results are the mean of three
different experiments ± standard deviation.
*Significant differences (P < 0Æ01) in compar-
ison with untreated (control) cells.
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incubation in serum-free medium plus cytokines, most of AML
blasts were in G0/G1 phase of the cell cycle as expected (Xu et al,
2003). Cytarabine (0Æ1 lmol/l for 24 h) slightly increased the
percentage of sub-G1 (apoptotic cells). Deguelin (10 nmol/l for
24 h) did not significantly alter the cell cycle of AML blasts.
However, when cells treated with deguelin were exposed to
cytarabine, the percentage of apoptotic cells rose substantially.
We next investigated whether deguelin could increase sensitivity
to cytarabine of normal CD34+ cells (Fig 5B). After a 24-h
treatment, the combination of cytarabine and deguelin did not
increase the percentage of apoptotic cells over cytarabine alone,
as shown by Annexin V staining. These results demonstrated a
fundamental difference in the sensitivity to deguelin of leukae-
mic cells versus normal CD34+ progenitors.
Discussion
The resistance of many types of neoplasia to conventional
therapies is a major factor undermining successful cancer
treatment. The PI3K/Akt pathway is rapidly emerging as a key
mediator of drug resistance in tumour cells. As Akt is usually
activated through PI3K, inhibitors that target PI3K (LY294002,
wortmannin) have been extensively investigated as anti-cancer
molecules. Numerous studies have established the potential
utility of these PI3K inhibitors as cancer therapies. However,
the toxicity of these PI3K inhibitors and their scarce water
solubility has precluded their therapeutic use to date (West
et al, 2002).
Deguelin is a naturally occurring rotenoid isolated from
several plant species that has been recently demonstrated to be
capable of inhibiting PI3K in premalignant and malignant
human bronchial epithelial cells (Chun et al, 2003).
Here, we investigated whether or not deguelin could
increase sensitivity to chemotherapeutic drugs of human acute
leukaemia cell lines with an active PI3K/Akt pathway. We
found that deguelin, when employed for 24 h at 10 nmol/l,
caused an S phase arrest of U937 cells, with interference of
progression to G2/M phase. This is in agreement with Chun
et al (2003). Deguelin, when employed alone up to a concen-
tration of 10 nmol/l for 24 h, did not significantly increase the
apoptotic rate of U937 cells. However, when the concentration
was increased to 100 nmol/l, deguelin induced apoptotic cell
death in these cells. This is consistent with the observation that
deguelin increased apoptosis of human bronchial cells (Chun
et al, 2003). It is very interesting that these concentrations fall





































Fig 3. Effects of deguelin on survival, Akt
phosphorylation, and on EPO- and SCF-
dependent erythroid differentiation of cultured
human CB CD34+ cells. (A) effect on apoptosis.
Cells were plated in 24-well dishes at 2 · 106
cells/ml in complete medium lacking or con-
taining the indicated inhibitors, and incubated
for up to 2 d. Wortmannin concentration was
100 nmol/l. Apoptotic cells were evaluated by
flow cytometry analysis. Results are the mean of
three different experiments ± standard devi-
ation. The asterisks indicate significant differ-
ences (P < 0Æ01) in comparison with untreated
(control) cells. (B) Western blot analysis for Akt
phosphorylation of CD34+ cells. Protein samples
blotted to nitrocellulose sheets were probed ei-
ther with antibodies to total Akt or to p-Akt
forms. The blots in B are representative of three
separate experiments. In A and B the Akt
inhibitors had been present since cell plating.
(C) CD34+ cells were immunophenotyped
immediately after cell isolation or cultured for
6 d in the presence of 5 U/ml erythropoietin
(EPO) and 50 ng/ml SCF. Wortmannin
(100 nmol/l) or deguelin (10 nmol/l) were
added at time 0 and after 3 d. Samples were
analysed by flow cytometry for GPA and CD71
expression. The percentage of GPA+ cells is
indicated in each histogram.
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Deguelin (10–100 nmol/l) induced Akt dephosphorylation,
however, it did not downregulate either p44/42 or p38 MAP
kinase phosphorylation levels. Deguelin was able to sensitize
U937 cells to two chemotherapeutic drugs used for the
treatment of AML. Moreover, deguelin sensitized AML blasts
to cytarabine, even if it did not markedly affect the cell cycle of
these cells.
Previous results have suggested that pharmacological inhib-
itors of PI3K such as wortmannin and LY294002, negatively
affect the survival of leukaemic cells, while sparing normal
bone marrow or umbilical CB CD34+cells (Xu et al, 2003).
Our findings, obtained with CB CD34+ cells, have confirmed
that wortmannin (100 nmol/l) is not toxic for these cells. They
have also shown that deguelin, if used at 10 nmol/l, did not
negatively affect the survival rate of haematopoietic progen-
itors. In contrast, if deguelin was used at 100 nmol/l, it caused
a significant increase in the percentage of apoptotic CB CD34+
cells. It is important to emphasize here, that a 10 nmol/l
concentration of deguelin lowered the levels of p-Akt in CB
CD34+ cells, whereas a 100 nmol/l caused a complete
dephosphorylation of Akt. Conceivably, a total loss of p-Akt
decreases the survival rate of CB CD34+ cells. In this context, it
should not been overlooked that a functioning PI3K/Akt
signalling is required for normal haematopoiesis, as erythro-
poietin activates Akt in CD34+ haematopoietic progenitor cells
(Myklebust et al, 2002), while inhibition of this pathway
suppresses myeloid progenitor cell differentiation (Lewis et al,
2004). It has been shown that LY294002, a PI3K inhibitor,
severely impairs the SCF- and EPO-driven erythroid differen-
tiation of CD34+ haematopoietic progenitor cells (Myklebust
et al, 2002). For this reason, we analysed the effect of deguelin
on EPO- and SCF-induced erythroid differentiation of CB
CD34+ cells. Deguelin (10 nmol/l) was found to be far less
effective than wortmannin in blocking the differentiation
process of CD34+ haematopoietic progenitors. It might be that
the different effects of deguelin and wortmannin on in vitro
erythropoiesis depend on the fact that wortmannin, apart from
PI3K, also inhibits phospholipase C, D and A2, whose activities
are stimulated by EPO and SCF (Mason-Garcia & Beckman,
1992; Clejan et al, 1996; Kozawa et al, 1997; Roberts et al,
1999; Boudot et al, 2003).
However, a concentration of 10 nmol/l of deguelin was
sufficient to markedly increase the sensitivity of human
leukaemia cells to chemotherapeutic drugs. Moreover, a
10 nmol/l deguelin concentration dramatically decreased
p-Akt levels of AML blasts and increased the sensitivity of
these cells to cytarabine. Although these experiments were
performed in vitro and the number of investigated patients was
limited, taken together they suggest that deguelin, when used
at certain concentrations, might not exert a strong toxic effect
on normal haematopoietic cells in vivo, as suggested also by the
experiments in which deguelin was combined with cytarabine
treatment in CD34+ cells. One of the patients employed in this
study had promyelocytic leukaemia. Usually, this form of
leukaemia is sensitive to treatment with retinoids, although
resistance to retinoids has been reported (Gallagher, 2002).
Thus, it might be envisaged that, in the future, a combination
therapy consisting of traditional chemotherapy plus inhibitors
of the PI3K/Akt would be of clinical benefit for these patients.
It might also be that deguelin would be useful to overcome
retinoid resistance, as we have shown for other inhibitors of
the PIK3/Akt axis (Martelli et al, 2003; Neri et al, 2003).
Overall, the present results are in agreement with our own
findings obtained with selective Akt inhibitors, which en-
hanced sensitivity of cells with an active PI3K/Akt pathway to
chemotherapeutic drugs (Martelli et al, 2003; Tabellini et al,
2004). However, an aspect, which needs to be emphasized is
that, at present, there is no information about the pharma-
cokinetics of these Akt inhibitors. Moreover, it is not known
whether it is possible to administer them intravenously or if
they will cause serious side effects. These Akt inhibitors belong
to the same family of chemicals as DPIEL (D-3-Deoxy-
phosphatidyl-myoinositol ether lipid), which, when given
intravenously to rats, caused severe haemolysis (Gills &
Dennis, 2004). In contrast, deguelin could be safely adminis-
tered intravenously and studies on its pharmacokinetics
have already been performed in rats (Udeani et al, 2001).
The results of this investigation showed that a 1 lmol/l
concentration of deguelin was achievable in a variety of tissues
in vivo after intravenous delivery. Moreover, this dosage was
not toxic to rats.
Fig 4. Deguelin induces Akt dephosphorylation in AML blasts.
Western blot analysis for expression of total Akt, and Ser 473 p-Akt.
Cells were incubated with deguelin (10 nmol/l) for 24 h prior to lysate
preparations. Protein (80 lg/lane) was separated by SDS-PAGE and
blotted to nitrocellulose sheets. Blots are representative of three sep-
arate experiments.
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To date, the effects of PI3K/Akt inhibition are unknown in
humans. Tumour cells may be selectively sensitive to inhibition
because they often grow in hostile environments and would
therefore be likely to have a higher reliance on signalling
pathways for survival than normal cells. However, should
PI3K/Akt inhibitors cause severe toxicity as single agents, these
drugs may also find use as sensitizers to other forms of therapy
(as demonstrated here) and for this purpose lower, less toxic
doses might be efficacious.
Future work will need to address whether the potential of
deguelin as a PI3K/Akt inhibitor may be fully realized in cancer
treatment. If so, the combination of deguelin with conven-
tional or novel therapeutic agents may provide better treat-
ment for defeating those leukaemias that have become resistant
to therapy because of an upregulation of PI3K/Akt signalling.
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